Hemp Stocks

596 Kommentare / 0 neu
03.01.2014 11:44
#1
Bild des Benutzers b00n
Offline
Kommentare: 5227
Hemp Stocks

 

 

Uruguay, Colorado Konsum legal

Div. US Bundesstaaten haben Medizinisches Marijane legalisiert...

weitere werden folgen..

nebst uruguay werden wohl noch andere Staaten in America sur folgen.

 

ganzer Sektor hat also enormes Wachstumpotential.

jetzt gilt es mal den spreu vom weizen zu trennen.

 

 

Ich fange mal an..

 


 

Aufklappen

----gesperrt wegen gutmenschentum, wünsche an der stelle allen alles gute, wie immer. http://investorshub.advfn.com/boards/profilea.aspx?user=193864

15.02.2017 09:43
Bild des Benutzers Selector
Offline
Kommentare: 569

Einverstanden WinkBiggrinDirol

14.02.2017 17:14
Bild des Benutzers Emil
Offline
Kommentare: 2865

Danke @Selector.

Mir hat es gefallen und ich komme wieder, dann wenn die (Gewinn)mitnahmen vorbei sind. Das Quartalsergebnis fand ich super. Good

https://de.wikipedia.org/wiki/EBITDA  Wink

 

Emil

14.02.2017 13:24
Bild des Benutzers Selector
Offline
Kommentare: 569

Hier also sind die Zahlen von WEED.

 

Der Text ist einigermassen lang, ausführlich und die Zahlentabelle braucht auch Platz. Deshalb anbei den untenstehenden Link:

http://www.newswire.ca/news-releases/canopy-growth-corporation-reports-third-quarter-fiscal-2017-financial-results-613685223.html

 

13.02.2017 17:00
Bild des Benutzers Emil
Offline
Kommentare: 2865

Ich bin schon mega gespannt, wie die WEED-Zahlen morgen kommen.

 

Hier hat noch einer einen Aufsatz geschrieben, war wohl Sonntagshobby  SmileBlum 3

http://www.microcapdaily.com/the-run-continues-on-canopy-growth-corp-com-npvotcmktstwmjf/117740/

Emil

10.02.2017 16:21
Bild des Benutzers Selector
Offline
Kommentare: 569

Aktuell: Preved

Canopy Health Innovations Enters into Agreement with Dr. Mark Ware 

 


SMITHS FALLS, ON, Feb. 10, 2017 /CNW/ - Canopy Health Innovations (CHI), the recently formed research incubator partly owned by Canopy Growth Corporation (TSX: WEED), has entered into a 3-year consulting agreement with EPIC Consulting Inc., the Quebec-based consulting firm of Dr. Mark Ware.

Canopy Health Innovations was established to research and develop clinically ready cannabis drug formulations and delivery systems for both human and/or animal patients targeting unmet medical needs in traditional pharmaceutical markets that could be disrupted by cannabis-based options. Under a framework agreement with CHI, Canopy Growth retains the right of first refusal to commercialize all resulting intellectual property developed by CHI globally.

"Canadian policy and regulations around cannabis are very progressive when compared to other jurisdictions around the world," said Marc Wayne, President and Director of CHI. "We have a unique opportunity here in Canada to study cannabis and develop products that will change the world. Bringing Dr. Ware in at this exciting moment to consult on our clinical research strategy is an important step towards our vision of bringing validated cannabis medicines to market as quickly as possible."

Dr. Mark Ware has been conducting medical cannabis research in Canada for more than 19 years and brings considerable expertise in the design of high quality clinical studies to evaluate the safety and efficacy of cannabinoids. "I am pleased to support the work that CHI is doing to develop cannabinoid medicines, and to help generate important data for patients and health care providers regarding the safety and efficacy of cannabis-based therapies" stated Dr. Ware. "EPIC was established to guide organizations in identifying and developing credible and evidence-based approaches to address the considerable gaps that currently exist in our understanding of the safe use of cannabis".

Dr. Ware's guidance will be instrumental for CHI research planning. With access to cannabis products from Canada's largest and most diverse production platform, Tweed's Dealer's License under Section 56 of the Controlled Drugs and Substances Act, and research data from studies operated by Canopy Growth subsidiaries, CHI's access to research tools is significant.  

It is an honour to add Dr. Ware's expertise and guidance as Canopy Health Innovations works to implement its vision of researching and developing cannabis medicines that will help patients worldwide.

About Canopy Health Innovations:
Canopy Health Innovations (CHI) operates as an independent and private collaborator of Canopy Growth Corporation and its subsidiaries. CHI is owned in part by Canopy Growth and qualified private investors. CHI's business model is to engage simultaneously in numerous research areas, with a strict focus on the creation and enhancement of intellectual property, which is then retained exclusively on a first-priority basis. Canopy Growth and its subsidiaries retain an exclusive, first priority right to license and commercialize intellectual property developed and owned by CHI.

 

SOURCE Canopy Growth Corporation
 

For further information: Marc Wayne, President & Director, Canopy Health Innovations, 416-894-0021

RELATED LINKS
http://canopygrowth.com/

Quelle:

http://www.newswire.ca/news-releases/canopy-health-innovations-enters-into-agreement-with-dr-mark-ware-613388233.html

 

sowie auch hier

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:WEED-2442936

 

 

08.02.2017 10:52
Bild des Benutzers shanik82
Offline
Kommentare: 8
Healthcare Tech. Heavily Influencing - Legal Canna Patient Ind.
07.02.2017 23:22
Bild des Benutzers Selector
Offline
Kommentare: 569

SmileDirol

Info: Die Zahlen von Q3 sind zu sehen am 14. Februar, Valentinstag.

 

Canopy Growth to release fiscal Q3 results Feb. 14

 

2017-02-07 15:20 ET - News Release

 

Mr. Bruce Linton reports

CANOPY GROWTH CORPORATION TO ANNOUNCE THIRD QUARTER FISCAL 2017 FINANCIAL RESULTS

Canopy Growth Corp. will release its financial results for the third quarter of fiscal 2017 ended Dec. 31, 2016, on Feb. 14, 2017.

Following the release of its third quarter fiscal 2017 financial results, Canopy Growth will host a conference call and audio webcast with Bruce Linton, chief executive officer, and Tim Saunders, chief financial officer, at 8:30 a.m. ET on the same day.

Webcast information

A live audio webcast will be available on-line.

Calling information

 

Toll-free dial-in number:  1-888-231-8191

International dial-in number:  647-427-7450

Conference ID:  55425439

 

Replay information

A replay of the call will be accessible by telephone until 11:59 p.m. ET on March 14, 2017.

 

Toll-free dial-in number:  1-855-859-2056

Replay password:  55425439

 

© 2017 Canjex Publishing Ltd. All rights reserved.

 

http://www.newswire.ca/news-releases/canopy-growth-corporation-to-announ...

07.02.2017 15:20
Bild des Benutzers shanik82
Offline
Kommentare: 8
Marihuana legal kaufen // Mission Money
31.01.2017 18:06
Bild des Benutzers Selector
Offline
Kommentare: 569

Wichtig: Bei CGC ändert das Symbol/Kürzel:

2017-01-30 20:15 ET - Symbol Change

See Symbol Change (C-CGC) Canopy Growth Corp

The Toronto Stock Exchange reports that Canopy Growth Corp. has changed its trading symbol to WEED, from CGC, effective at the open on Feb. 1, 2017.

© 2017 Canjex Publishing Ltd. All rights reserved.

 

Weitere Info von Montag: Smile

 

Mettrum's acquisition by Canopy Growth has court OK

 

2017-01-30 16:52 ET - News Release

See News Release (C-MT) Mettrum Health Corp

Mr. Ali Mahdavi of Mettrum reports

METTRUM RECEIVES COURT APPROVAL IN CONNECTION WITH PROPOSED PLAN OF ARRANGEMENT WITH CANOPY GROWTH CORPORATION

The Ontario Superior Court of Justice has issued a final order approving the proposed acquisition by Canopy Growth Corp. of all of the issued and outstanding common shares of Mettrum Health Corp. by way of a plan of arrangement, as previously announced by the companies on Dec. 1, 2016.

Completion of the arrangement remains conditional on certain closing conditions customary for transactions of this nature pursuant to the terms of the definitive arrangement agreement dated Nov. 30, 2016, as amended. Subject to the satisfaction or waiver of all such closing conditions, it is anticipated that the arrangement will be completed after the markets have closed on Jan. 31, 2017.

The arrangement, if completed, will result in the creation of a world-leading diversified cannabis company with six licensed facilities and a licensed production footprint of approximately 665,000 square feet with significant acreage for expansion. Following completion of the arrangement, Mettrum will become a wholly owned subsidiary of Canopy Growth, trading of Mettrum's common shares on the TSX Venture Exchange will be halted after closing on Jan. 31 and Mettrum's common shares will be delisted from the TSX Venture Exchange in the normal course shortly thereafter.

About Mettrum Health

Mettrum Health is a Tier 1 industry issuer listed on the TSX Venture Exchange. With three licences to produce and sell medical cannabis under the access to cannabis for medical purposes regulations, Mettrum Health is a leading producer and vendor of medical cannabis. In addition, through its wholly owned subsidiary Mettrum Hempworks, Mettrum also is a licensed producer and distribution of industrial cannabis (hemp) products, including Mettrum's functional food line, Mettrum Originals, under the industrial hemp regulations (Canada) issued pursuant to the Controlled Drugs and Substances Act (Canada).

About Canopy Growth

Canopy Growth is the world's leading diversified cannabis company, offering diverse brands and curated cannabis strain varieties in dried and oil extract forms. Through its wholly owned subsidiaries, Tweed, Tweed Farms and Bedrocan Canada, Canopy Growth operates three state-of-the-art production facilities with over half a million square feet of indoor and greenhouse production capacity. Canopy Growth has established partnerships with leading sector names in Canada and abroad.

We seek Safe Harbor.

© 2017 Canjex Publishing Ltd. All rights reserved

http://www.newswire.ca/news-releases/mettrum-receives-court-approval-in-connection-with-proposed-plan-of-arrangement-with-canopy-growth-corporation-612199513.html

 

 

 

 

 

 

 

 

 

28.01.2017 16:58
Bild des Benutzers Selector
Offline
Kommentare: 569

 

Info: SmileDirol

 

http://business.financialpost.com/news/fp-street/cannabis-producer-tweed-inc-triples-production-space-with-purchase-of-former-hershey-factory

 

Canopy Growth, Mettrum shareholders approve merger

 

2017-01-27 13:19 ET - News Release

See News Release (C-CGC) Canopy Growth Corp

Mr. Bruce Linton of Canopy Growth reports

CANOPY GROWTH AND METTRUM ANNOUNCE RESPECTIVE SHAREHOLDER APPROVALS OF THE PLAN OF ARRANGEMENT

At the special meetings of shareholders of Canopy Growth Corp. and Mettrum Health Corp. held in Smiths Falls, Ont., and Toronto, Ont., respectively, the companies' shareholders have approved Canopy Growth's acquisition of Mettrum by way of a plan of arrangement, as previously announced by the companies on Dec. 1, 2016.

Now that the requisite shareholder approvals have been obtained, a final order of the Ontario Superior Court of Justice approving the arrangement will be sought on Jan. 30, 2017. Provided that the final order is obtained, and the satisfaction or waiver of all other conditions specified in the definitive arrangement agreement dated Nov. 30, 2016, as amended, it is expected that the arrangement will be completed on or about Jan. 31, 2017.

Shareholders of Canopy Growth approved the ordinary resolution approving the issuance, or reservation for issuance, as the case may be, by Canopy Growth of up to 40 million common shares. The resolution was approved by 94.18 per cent of the votes cast by Canopy Growth shareholders present in person or represented by proxy. A total of 19.8 per cent of the issued and outstanding common shares of Canopy Growth were voted at the meeting.

The arrangement was approved by: (i) 99.76 per cent of the votes cast by Mettrum shareholders present in person or represented by proxy, and (ii) 99.69 per cent of the votes cast by Mettrum shareholders present in person or represented by proxy, excluding votes that may not be included in determining minority approval pursuant to the rules of Multilateral Instrument 61-101 -- protection of minority shareholders in special transactions. A total of 55.37 per cent of the issued and outstanding common shares of Mettrum were voted at the meeting.

"We are delighted that the shareholders of Canopy and Mettrum have demonstrated such strong support for bringing our two companies together," said Bruce Linton, chairman and chief executive officer, Canopy Growth. "Our focus remains on expanding production capabilities in order to capture market share through a variety of brands. Mettrum's strong growing platform and brand furthers this strategy."

The arrangement, if completed, will result in the creation of a world-leading diversified cannabis company with six licensed facilities and a licensed production footprint of approximately 665,000 square feet with significant acreage for expansion. Following completion of the arrangement, Mettrum will cease trading on the TSX Venture Exchange and will become a wholly owned subsidiary of Canopy Growth.

About Canopy Growth

Canopy Growth is a diversified cannabis company, offering diverse brands and curated cannabis strain varieties in dried and oil extract forms. Through its wholly owned subsidiaries, Canopy Growth operates numerous state-of-the-art production facilities with over 500,000 square feet of indoor and greenhouse production capacity.

About Mettrum Health

With three licences to produce and sell medical cannabis under the access to cannabis for medical purposes regulations, Mettrum Health is a leading producer and vendor of medical cannabis. In addition, through its wholly owned subsidiary, Mettrum Hempworks, Mettrum is a licensed producer and distribution of industrial cannabis (hemp) products, including Mettrum's functional food line, Mettrum Originals, under the industrial hemp regulations (Canada) issued pursuant to the Controlled Drugs and Substances Act (Canada).

We seek Safe Harbor.

© 2017 Canjex Publishing Ltd. All rights reserved.

 

http://www.newswire.ca/news-releases/canopy-growth-and-mettrum-announce-respective-shareholder-approvals-of-the-plan-of-arrangement-611986585.html

20.01.2017 09:58
Bild des Benutzers logn
Offline
Kommentare: 330
19.01.2017 22:22
Bild des Benutzers shanik82
Offline
Kommentare: 8
Cannabis-Medizin wird zur Kassenleistung
18.01.2017 08:40
Bild des Benutzers shanik82
Offline
Kommentare: 8
Lifestyle Delivery Systems mit disruptiven CannaStrips

Am Donnerstag habe ich in Frankfurt an einer Lunch-Präsentation mit Brad Eckenweiler, dem CEO der kanadischen Firma Lifestyle Delivery Systems (WKN: A14XHT), teilgenommen. Eckenweiler erklärte den rund 20 Teilnehmern das Geschäftsmodell der Gesellschaft und die Produkte.

Eckenweiler und das Team haben die sogenannten CannaStips entwickelt und patentiert. CannaStrips sind dünne Blättchen und enthalten Marihuana. Die CannaStrips sind auf der Zunge löslich und die über mehrere Stunden anhaltende Wirkung tritt laut Aussage des CEOs innerhalb kürzester Zeit ein.

Die CannaStrips werden in Kürze in vier verschiedenen Kategorien erhältlich sein. Je nach Anwendungsgebiet können die Konsumenten sich für ein schmerzlinderndes oder schlafförderndes Produkt für 1 USD erwerben. Die Marge liegt bei dem geschützten Produkt bei stolzen 87%. Der niedrige Preis hat das Potenzial zu einem disruptiven Albtraum für die Pharmabranche und dem illegalen Drogenhandel zu werden.

Spätestens im Januar 2017 sollen die CannaStrips in autorisierten Geschäften in Kalifornien, USA, frei erhältlich sein. Aus rechtlichen Gründen soll vorerst der Vertrieb auf den Sonnenstaat fokussiert sein. Wer vor 1980 geboren ist, kann sich wahrscheinlich noch daran erinnern, mit welcher Kreativität die Konsumenten zu Beginn der 90er Jahre die ersten Red Bull Dosen von Österreich nach Deutschland schmuggelten. Dass die Inhaltsstoffe von Red Bull damals hierzulande verboten waren, entwickelte sich zusammen mit aufkommenden Mythen zu einer staatlich-geförderten Marketingmaßnahme.

Das Unternehmen führt momentan eine Finanzierung in Höhe von 5 Mio. CAD zu 0,75 CAD pro Aktie durch. Die neuen Aktien werden zusammen mit einem halben Warrant mit einem Bezugsrecht einer neuen Aktie zu 1,50 CAD ausgegeben. Laut Eckenweiler ist die Finanzierung bereits mehrfach überzeichnet. Noch im Juni dieses Jahres wechselten die Aktien bei unter 0,10 CAD die Besitzer. Nur rund vier Monate später erreichten die Aktien im Oktober den Preis von 1,00 CAD. Am Freitag gingen die Aktien an der Heimatbörse in Kanada bei 0,69 CAD aus dem Handel.

Bei dieser plausibel und genial klingenden Geschäftsidee halte ich drei Szenarien für möglich: 1. Die CannaStrips werden ein Erfolg und das Unternehmen ist bald nicht mehr unter 40 Mio. CAD Wert, sondern geht in Richtung 1 Milliarde CAD Bewertung. 2. CannaStrips könnten ein Ladenhüter werden und in ein paar Jahren redet niemand mehr darüber oder 3., dass das Unternehmen so erfolgreich wird, dass es mit rechtlichem Gegenwind zu kämpfen hat. In diesem Zusammenhang spielt die neue Trump-Regierung auf Bundesebene eine wichtige Rolle. Wir werden sehen.

Quelle:http://www.derfinanzinvestor.de/Kommentare/Lifestyle-Delivery-Systems-mit-disruptiven-CannaStrips

17.01.2017 09:43
Bild des Benutzers Peter-Silie
Offline
Kommentare: 107

Auf www.reddit.com/r/weedstocks/ gäbe es ein weiteres Forum mit mehr Beiträgen (ist halt in Englisch). Dort werden auch ziemlich alle News sofort gepostet.

16.01.2017 22:28
Bild des Benutzers shanik82
Offline
Kommentare: 8
LDS News
16.01.2017 20:24
Bild des Benutzers Selector
Offline
Kommentare: 569

 

Info von CGC/Tweed  Smile Dirol

 

SMITHS FALLS, ON, Jan. 16, 2017 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: CGC) has closed the acquisition of the property at 1 Hershey Drive that currently houses Canopy Growth's headquarters and the Tweed Inc. (Tweed) production facilities.

"Increasing the scale of our cannabis production capacity is vitally important to our operations," said Bruce Linton, Chairman and CEO of Canopy Growth. "Even as a diversified producer using greenhouse growing and indoor growing facilities, we know there will be a need for commercial processing space that can be used to convert cannabis and cannabinoids into higher margin products like edibles, as well as complimentary products such as vape pens, or sophisticated medical delivery options that may be allowed under future legal frameworks. Almost tripling the footprint of our headquarters means more potential for our business, for the economy of Smiths Falls, and for Tweed's customers."

The entire 472,000 sq. ft. footprint could almost triple current production and processing capacity, making it by far the largest indoor cannabis production facility in Canada and likely the world. The 42-acre site could also house hundreds of thousands of square feet of additional production and processing space, either indoors or in greenhouse growing platforms.

Tweed has already transformed 168,000 sq. ft. of licensed space into Canada's most innovative cannabis production space. Twelve of 39 potential growing rooms are operational with another 12 multi-level growing rooms under construction and nearing completion. An R&D area has been used to drive innovation with some of Canada's leading researchers and universities. Oil extraction capabilities, a separate Dealer's Licence area, an in-house Quality Assurance lab, and the industry's only seed breeding area have all been added and brought online in the last three years.

The building, property and chattels were acquired for $6.6 million, of which $923,980 was settled with the issuance of 94,397 common shares of Canopy Growth, based on a 5-day VWAP of $9.7882 ending the day before closing.  The remainder was paid in cash on closing. As a part owner of the facility prior to the transaction, Bruce Linton received 70,800 of the 94,397 shares issued. These shares are subject to a 4-month lockup.

The acquisition is considered a "related party transaction" within the meaning of Multilateral Instrument 61-101 — Protection of Minority Security Holders in Special Transactions ("MI 61-101") because Bruce Linton, a director and officer of Canopy Growth is also a shareholder of the vendor Tweed Hershey Drive Inc. MI 61-101 provides that, unless exempted, an issuer proposing to undertake a related party transaction is required to prepare a formal valuation of the subject matter of the proposed transaction and to provide holders of the class of affected securities a summary of such valuation. MI 61-101 also requires that, unless exempted, the issuer seek approval of the transaction by a majority of the votes cast by the "minority" holders of the affected securities.

To ensure a fair valuation, John Bell, an independent Director of Canopy Growth led the purchase negotiation.  The Company also obtained an independent appraisal to support the final price negotiated.

Canopy Growth has relied on an exemption available pursuant to MI 61-101 from the formal valuation and minority approval requirements. MI 61-101 provides that if, at the time the transaction is agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for the transaction, insofar as it involves interested parties, exceeds 25% of the issuer's market capitalization (calculated in accordance with MI 61-101), the formal valuation and minority approval requirements do not apply to such transaction. The acquisition of 1 Hershey Drive is exempt from the formal valuation and minority approval requirements of MI 61-101 because neither the fair market value of 1 Hershey Drive nor the fair market value of the purchase price for the acquisition of 1 Hershey Drive exceeds 25% of Canopy Growth's market capitalization.

The consideration paid was provided for in the Use of Proceeds in a recently completed bought deal, which closed on December 22, 2016.  The Smiths Falls facility and significant improvements completed, underway and planned will act as an important asset and security that could be viewed favourably by commercial institutional lenders to recycle the equity invested and finance future expansion plans with non-dilutive funding at competitive rates. The Company previously leased Tweed's production and office space at 1 Hershey Drive, an arrangement that permitted the Company to defer the financial burden of unused portions of the building, which have sat vacant since 2008 when Hershey Canada Inc. vacated the property, until the commercial opportunity supported the need to expand the Company's operating footprint.

"The future looks bright for Tweed and Canopy Growth's operations in this facility," continued Linton. "It might even be time to reopen the famous Visitor Centre and start training tour guides."

Here's to Future Growth.

About Tweed
Tweed is a globally recognized marijuana production brand. It has built a large and loyal following by focusing on quality products and meaningful customer relationships. Tweed doesn't just sell marijuana, it facilitates a conversation about a product we've all heard about but haven't met intimately yet. It is approachable and friendly, yet reliable and trusted. As marijuana laws liberalize around the world, Tweed will expand its leading Canadian position around the globe. Learn more at www.tweed.com.

About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis company, offering diverse brands and curated cannabis strain varieties in dried and oil extract forms. Through its wholly‑owned subsidiaries, Canopy Growth operates numerous state-of-the-art production facilities with over half a million square feet of indoor and greenhouse production capacity. Canopy Growth has established partnerships with leading sector names in Canada and abroad. For more information visit www.canopygrowth.com.

Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation, Tweed Inc., Tweed Farms Inc. or Bedrocan Canada Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection. The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corp. does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

SOURCE Canopy Growth Corporation
 

For further information: Jordan Sinclair, Director of Communications, Jordan@tweed.com, 613-769-4196; Investor Relations, Tyler Burns, Tyler.burns@canopygrowth.com, 855-558-9333 ex 122; Director: Bruce Linton, tmx@tweed.com

RELATED LINKS
http://canopygrowth.com/

http://www.newswire.ca/news-releases/canopy-growth-triples-tweeds-produc...

09.01.2017 12:25
Bild des Benutzers petra129
Offline
Kommentare: 33

CAN MJ CGC MT APH ACB OGI Technical Analysis Chart 1/6/2017 by ChartGuys.com

 

https://www.youtube.com/watch?v=cCwojF_l40w&t=22s&hd=1

09.01.2017 12:04
Bild des Benutzers petra129
Offline
Kommentare: 33

@Peter... ja habe mir auch wieder ein paar geposchtet - allerdings teurer als mein vorheriger Abgang Sad

hier noch zwei kurze Videos über Marijuana:

https://www.youtube.com/watch?v=n2KozLOjxXE&hd=1

https://www.youtube.com/watch?v=ENRa3-R6Ogw&hd=1

06.01.2017 10:54
Bild des Benutzers Peter-Silie
Offline
Kommentare: 107

Hab mir mal noch eine Portion APH.TO ins Depot gelegt Smile sollte die Fusion von CGC und MT zustandekommen, wären sie dann die 2 grössten Produzenten in Kanada, positiv ist auch, dass sie bereits Gewinn schreiben.

05.01.2017 21:37
Bild des Benutzers shanik82
Offline
Kommentare: 8
LDS - Canna Strips
03.01.2017 22:55
Bild des Benutzers Selector
Offline
Kommentare: 569

Danke für die Info. Hier noch von heute CGC's Jahresrückblick:

Wink

 

Canopy comments on cannabis product recalls in 2016

 

2017-01-03 13:29 ET - News Release

 

Mr. Bruce Linton reports

CANOPY GROWTH CORPORATION COMMENTS ON THE YEAR THAT WAS 2016

Canopy Growth Corp. is offering the following commentary on the events of late 2016.

Transitioning Canadians into the legal cannabis system with the appropriate checks and balances has been very successful to date. The number of authorized medical cannabis users tripled in 2016 as health care professionals and individuals became increasingly aware of the emerging regulated system, and as the system itself evolved to better meet Canadians' needs.

Since May, 2014, when Tweed shipped its first gram, its facilities have evolved and become more efficient. Each stage of production and processing has dozens of standard operating procedures that make its products better and safer. Through hard work and a culture of improving every aspect of the company's operations as it grows, Canopy Growth has earned almost a quarter of the market share and developed a strong record of compliance across multiple facilities.

Canada is ahead of the global curve with regards to cannabis regulation. The system in place today has successfully introduced over 100,000 Canadians to a legal source of cannabis for medical purposes. The success of the access to cannabis for medical purposes regulations is evident in its growth, which has continued at a rate of approximately 10 per cent per month for more than two straight years. Quality of product is improving across the sector, while average prices have come down. Patients now have cannabis oils and capsules to choose from, in addition to a variety of dried cannabis options.

Late last year, the company's sector was met with two announced product recalls and some related negative media coverage. These instances were of course unfortunate. As neither recall was related to Canopy Growth or its subsidiaries, Canopy is in no position to comment on the details related to the product recalls. One of the companies, however, is set to join the Canopy family, and the company remains proud of the reputation Mettrum has built for its quality products, customer support and physician outreach.

It is important to note that recalls are not the sign of a system in disarray; rather, they are signs that the system is working to protect Canadian patients. This is true of all regulated industries, from food production to medical production, but it is especially important in a sector such as the cannabis industry, which remains in its infancy and subject to incredible scrutiny.

All licensed producers are highly regulated, tracking every plant from seed to sale, testing product for release and maintaining samples in case further testing is required. Additionally, and unique to the company's sector given the direct relationship it has with its patients, every licensed producer has procedures in place to contact every one of its clients if a recall or other customer notification needs to occur. Upon discovering anything warranting a recall, such as the presence of unapproved treatment products, a licensed producer will ensure that impacted customers are identified, and advised of the recall and of any potential risks associated with product consumption. Furthermore, substantial testing and reviews of procedures will occur to ensure that corrective actions are put in place and implemented.

In the case of Mettrum's disclosed recall, it was concluded by Health Canada and external experts that the recall constituted a Type 3 recall, defined by Health Canada as a situation in which the use of, or exposure to, a product is not likely to cause any adverse health consequences. All patients who are potentially impacted are notified, corrective actions are put in place, and existing product and procedures retested and examined.

Looking to the future, there are no signs of things slowing down for the company's sector or the company. In spite of the fact that illegal sources exist, Canadians requiring cannabis for medical purposes increasingly place their trust in a system that delivers high-quality products, and has safeguards in place to recognize and react in the rare cases when that standard is not met. The company is not perfect, nor is the system in which it operates. There will be bumps along the road, but, for a new sector, there is a lot to take pride in.

As the company enters a new year that will undoubtedly see the topic of cannabis debated everywhere from the water cooler to the floor of the House of Commons, it is important that the successes of the current system are recognized, its shortcomings are identified and addressed, and a uniquely Canadian cannabis sector is created that can continue to improve the lives Canadians, and ensure a safe, reliable and regulated supply of cannabis products.

About Canopy Growth

Canopy Growth is a world-leading diversified cannabis company, offering diverse brands and curated cannabis strain varieties in dried and oil extract forms. Through its wholly owned subsidiaries, Canopy Growth operates numerous state-of-the-art production facilities with over 500,000 square feet of indoor and greenhouse production capacity.

We seek Safe Harbor.

© 2017 Canjex Publishing Ltd. All rights reserved.

03.01.2017 09:25
Bild des Benutzers petra129
Offline
Kommentare: 33

http://finance.yahoo.com/video/oddball-marijuana-laws-books-234921110.html

....keine spezifischen Aktien - aber von allgemeinem Interesse denke ich.

23.12.2016 18:54
Bild des Benutzers Emil
Offline
Kommentare: 2865

Also dies finde ich mega cool:

Heute,

https://www.tweed.com/blogs/blog

@ REMI,

 

Emil

21.12.2016 23:35
Bild des Benutzers Selector
Offline
Kommentare: 569

Und dann noch dies:

 

Canopy Growth unit closes $7-million financing

 

2016-12-21 14:58 ET - News Release

 

Mr. Bruce Linton reports

CANOPY HEALTH INNOVATIONS CLOSES FINANCING & ANNOUNCES LEADERSHIP APPOINTMENT

Canopy Growth Corp.'s recently formed Canopy Health Innovations (CHI) has closed an offering to sell common shares in CHI for gross proceeds of approximately $7-million. CHI will use the proceeds to establish general operations and begin clinical research (in partnership with licensed third parties, including Canopy Growth) into the effectiveness of clinically ready whole-plant cannabis drug formulations and dose delivery systems on specific indications.

CHI will operate as a pure research incubator and is strategically positioned and focused on creating an IP portfolio that can be built into commercial opportunities for Canopy Growth and its subsidiaries.

Pursuant to agreements entered into between CHI and Canopy Growth, Canopy Growth and its subsidiaries will work closely with CHI, whereby Canopy Growth will act as a primary supplier of cannabis products for clinical research; as a research partner through its subsidiary Tweed Inc., which recently acquired a controlled drugs and substance dealer's licence from Health Canada, allowing it to, among other things, possess cannabis and cannabis byproducts for the purposes of analytical testing; and in the commercialization of IP created by CHI.

"Canada is in a unique leadership position with respect to cannabis research and cannabis IP," said Bruce Linton, chairman of CHI and chairman and chief executive officer of Canopy Growth. "Our intention with CHI is to build an extension of the business that is dedicated to product specialization. By defining, in clinical terms, how to apply specific cannabis profiles and delivery systems to certain conditions, we can drive physician acceptance and grow the market at the same time."

Also, Marc Wayne will join CHI as founding president and director. Mr. Wayne is well regarded as a pioneer in the Canadian medical cannabis field, having both co-founded Bedrocan Canada, one of Canada's first licensed producers, and the Cannabis Canada Association (formally CMCIA), acting as its founding chair. Mr. Wayne was also instrumental in helping to develop the Canadian Consortium for the Investigation of Cannabinoids (CCIC) and turning it into a global innovator in education and research on the medical uses of cannabis. With his years of start-up and executive management experience, Mr. Wayne is ideally suited to lead this health- and research-focused enterprise during this critical time for cannabis research.

"This is a very exciting time for cannabis research and the possibility to take whole-plant cannabis therapies to another level," said Mr. Wayne. "Canada is well positioned with its current regulatory environment to lead in this area. The calls for more research into cannabis have been heard, and I am honoured to have the opportunity to lead CHI as a credible first mover into this area."

Effective upon the closing of the offering, Mr. Wayne has resigned his position as managing director of Canopy Growth and as president of Bedrocan Canada Inc. in order to focus his attention on CHI. The Canopy Growth management team and board of directors wish to deeply thank Mr. Wayne for his instrumental role in forming Canopy Growth and his dedication to medical cannabis work, which will continue and accelerate at CHI.

CHI is currently owned in part by Canopy Growth and private investors. The corporate vision of CHI is to increase the understanding of cannabis-based therapies through research, drive product innovation and build intellectual property in the medical cannabis industry.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

 

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:CGC-2432341

 

 

 

 

21.12.2016 13:46
Bild des Benutzers Selector
Offline
Kommentare: 569

Hier aber kann man was lesen betr. CGC:  Wink

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:CGC-2432094

 

Canopy Growth to list 5,662,000 more shares on TSX

 

2016-12-20 18:24 ET - Prospectus Approved

 

Canopy Growth Corp. will list an additional 5,662,000 shares at the open on Dec. 22, 2016, according to the Toronto Stock Exchange. As stated in the company's Dec. 16, 2016, short form prospectus, Canopy Growth will issue 5,662,000 shares at $10.60 per share. It has granted to the underwriters an overallotment option to buy 849,300 more shares at the same price for 30 days following the closing of the offering.

© 2016 Canjex Publishing Ltd. All rights reserved.

 

 

 

 

20.12.2016 09:57
Bild des Benutzers Peter-Silie
Offline
Kommentare: 107

petra129 hat am 16.12.2016 - 19:05 folgendes geschrieben:

@Peter-Silie - ich versteh das auch nicht. Im Mettrum Forum liest man nichts, im Canopy-Forum findet man etwas, aber den wirklichen Durchblick haben die wohl auch (noch) nicht.

http://www.stockhouse.com/companies/bullboard/v.cgc/capital-gold-corpora...

vielleicht findest Du bei Canopy etwas in nächster Zeit?!?!

 

Die Fusion muss ja noch genehmigt werden im Januar..Sonst sehe ich eigentlich keine anderen Gründe. 

 

19.12.2016 16:17
Bild des Benutzers petra129
Offline
Kommentare: 33

CAN MJ CGC MT APH ACB SPRWF OGI Technical Analysis Chart 12 /16/2016 by ChartGuys.com

 

https://www.youtube.com/watch?v=8IZg83hYVCI

Video mit Charts ab 1:43

16.12.2016 19:05
Bild des Benutzers petra129
Offline
Kommentare: 33

@Peter-Silie - ich versteh das auch nicht. Im Mettrum Forum liest man nichts, im Canopy-Forum findet man etwas, aber den wirklichen Durchblick haben die wohl auch (noch) nicht.

http://www.stockhouse.com/companies/bullboard/v.cgc/capital-gold-corpora...

vielleicht findest Du bei Canopy etwas in nächster Zeit?!?!

16.12.2016 15:53
Bild des Benutzers Peter-Silie
Offline
Kommentare: 107
MT / CGC Merger

Hallo zusammen Smile

 

Der Merger von Canopy und Mettrum steht ja kurz bevor, kann jemand erklären, warum eine so grosse Differenz zum Wandlungspreis besteht? Pro Mettrum Aktie bekommt man ja ca. 0.71 CGC.. Der Kurs von Mettrum steht aber einiges tiefer? Ist eine zu grosse Unsicherheit vorhanden, dass der Zusammenschluss nicht durchgeführt wird?

 

Grüsse Peter-Silie

14.12.2016 16:03
Bild des Benutzers logn
Offline
Kommentare: 330

Selector hat am 06.12.2016 - 12:53 folgendes geschrieben:

Danke euch für die Infos.

@logn

betr. Marapharm sind diese nicht zum Onlinetrading freigegeben (OTC) ?  und falls die zum Pennystock werden könnten,

fliegen sie in USA raus. Lasse ich.

Info bei Cash: Dieser Titel ist nicht zum Handel im e-banking freigeschaltet. Für telefonischen Handel oder Auskunft wählen Sie bitte 00800 0800 55 55.

Listing: CNQ, FRA, STU, OTN, NQB und FSE (Quelle: Telekurs).

 

Marapharm Ventures Inc. beginnt mit den Bauarbeiten auf seinem Grundstück in Las Vegas (Nevada)

Kelowna, British Columbia, Kanada - 7. Dezember 2016, Marapharm-Symbole: Kanada - CSE:MDM / Deutschland - FWB:2M0 / Vereinigte Staaten - OTCQB:MRPHF

Marapharm Ventures Inc. (Marapharm) gibt bekannt, dass die Bauarbeiten auf seinem 7 Acres grossen Grundstück im Apex Industrial Park in Las Vegas (Nevada) nun im Gange sind. Am 14. November 2016 wurde bekannt gegeben, dass zwei erste Gebäude mit einer Fläche von 5.000 Quadratfuss bei CECO Building Systems beauftrag wurden. Der Auftrag ist nun fertiggestellt, die Gebäude wurden gefertigt und werden nach Plan am 19. Dezember 2016 angeliefert werden. Die ersten Platzbauarbeiten wurden abgeschlossen und der Gebäudestandort wird von Patriot Grading für die Schalungen und die Plattengründung vorbereitet. Eine 12 mal 20 Fuss grosse Reklametafel mit dem Logo des Unternehmens und dem Slogan Watch us grow wird vor Ort aufgestellt werden. Der Bebauungsplan und die Genehmigungen für das erwartete Staubaufkommen liegen vor. Eine temporäre Umzäunung wurde errichtet. Mit Master Association wurde eine Vereinbarung hinsichtlich der Schuttreste, die für den Bau notwendig sind, getroffen und das Material wird Marapharm kostenlos zur Verfügung gestellt.

Las Vegas verzeichnet jedes Jahr mehr als 50 Millionen erwachsene Besucher. Marihuana wurde in Nevada nun auch als Genussmittel legalisiert. Und wir erreichen die von uns gesteckten Ziele, sagte Linda Sampson, CEO von Marapharm.

ÜBER MARAPHARM VENTURES INC.

www.marapharm.com

Marapharm ist im Besitz von 300.000 Quadratfuss umfassenden lizensierten Flächen und Anlagen für den Anbau und Verkauf von medizinischem Marihuana in den US-Bundesstaaten Washington und Nevada. In Kanada beantragte Marapharm vor zweieinhalb Jahren eine Produktions- und Verkaufslizenz gemäss den MMPR-Richtlinien und hat die Unbedenklichkeitsbescheinigungen erhalten. Der Antrag wird derzeit dem eingehenden Prüfverfahren unterzogen. Im September 2016 wurde Marapharm von Health Canada kontaktiert und darüber informiert, dass es für Marapharm zulässig ist, den derzeit von Health Canada geprüften Antrag zu ergänzen und die vor kurzem eingeführten ACMPR-Bestimmungen einzubinden.

Weitere Informationen zu den Betriebs- oder Finanzergebnissen von Marapharm entnehmen Sie bitte den bei den zuständigen Wertpapieraufsichtsbehörden vorliegenden Berichten, die über die CSE-Website (www.thecse.com), die OTC-Website (www.otcmarkets.com) und die SEDAR-Website (www.sedar.com) unter dem Unternehmensprofil von Marapharm Ventures Inc. eingesehen werden können.

 

Seiten